Pharmacotherapy for NASH: Current and emerging
Top Cited Papers
- 1 February 2018
- journal article
- review article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 68 (2), 362-375
- https://doi.org/10.1016/j.jhep.2017.10.015
Abstract
No abstract availableThis publication has 74 references indexed in Scilit:
- The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysisJournal of Hepatology, 2011
- Meta‐analysis: pioglitazone improves liver histology and fibrosis in patients with non‐alcoholic steatohepatitisAlimentary Pharmacology & Therapeutics, 2011
- Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cellsClinical and Experimental Immunology, 2011
- Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary OsteoporosisCurrent Osteoporosis Reports, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisThe New England Journal of Medicine, 2010
- Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2009
- CCR2 promotes hepatic fibrosis in miceJournal of Hepatology, 2009
- The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLDJournal of Hepatology, 2007
- Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary PreventionJAMA, 2007
- Design and validation of a histological scoring system for nonalcoholic fatty liver diseaseJournal of Hepatology, 2005